m6A‐related lncRNAs as potential biomarkers and the lncRNA ELFN1‐AS1/miR‐182‐5p/BCL‐2 regulatory axis in diffuse large B‐cell lymphoma

Abstract

AbstractDiffuse large B‐cell lymphoma (DLBCL) is the most common lymphoid subtype. However, unsatisfactory survival outcomes remain a major challenge, and the underlying mechanisms are poorly understood. N6‐methyladenosine (m6A), the most common internal modification of eukaryotic mRNA, participates in cancer pathogenesis. In this study, m6A‐associated long non‐coding RNAs (lncRNA) were retrieved from publicly available databases. Univariate, LASSO, and multivariate Cox regression analyses were performed to establish an m6A‐associated lncRNA model specific to DLBCL. Kaplan–Meier curves, principal component analysis, functional enrichment analyses and nomographs were used to study the risk model. The underlying clinicopathological characteristics and drug sensitivity predictions against the model were identified. Risk modelling based on the three m6A‐associated lncRNAs was an independent prognostic factor. By regrouping patients using our model‐based method, we could differentiate patients more accurately for their response to immunotherapy. In addition, prospective compounds that can target DLBCL subtypes have been identified. The m6A‐associated lncRNA risk‐scoring model developed herein holds implications for DLBCL prognosis and clinical response prediction to immunotherapy. In addition, we used bioinformatic tools to identify and verify the ceRNA of the m6A‐associated lncRNA ELFN1‐AS1/miR‐182‐5p/BCL‐2 regulatory axis. ELFN1‐AS1 was highly expressed in DLBCL and DLBCL cell lines. ELFN1‐AS1 inhibition significantly reduced the proliferation of DLBCL cells and promoted apoptosis. ABT‐263 inhibits proliferation and promotes apoptosis in DLBCL cells. In vitro and in vivo studies have shown that ABT‐263 combined with si‐ELFN1‐AS1 can inhibit DLBCL progression.